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costs. In the US, the family members’ aggregate productivity loss was estimated 
at $3.3 billion. Spouses of prostate cancer patients were found to have incurred 
$1,309 in lost productivity. Spouses’ aggregate productivity loss was estimated at 
$1.3 billion. Sensitivity analysis of the aggregated US estimates revealed that the 
total lost productivity of family members as a result of prostate cancer ranged 
from $2.2 billion to $4.6 billion. For spouses of prostate cancer patients, the 
results of the sensitivity analysis ranged from $0.9 billion to $1.7 billion. 
CONCLUSIONS: These findings indicate that prostate cancer has a significant 
impact on work productivity of prostate cancer patients’ families and spouses. 
However, there are few resources available to assist prostate cancer patients and 
families in dealing with the disease from a psychosocial aspect. Research is 
warranted to further assess the negative effects of prostate cancer on families.  
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OBJECTIVES: To obtain the standard treatment cost of female breast cancer with 
different TNM Stage. METHODS: The treatment cost of female breast cancer 
consisted of direct medical expenditure, direct non-medical expenditure, and 
indirect expenditure. Extracting previous data, calculating by clinical pathway, 
face-to-face interviewing, and telephone interviewing were adopted to estimate 
the treatment cost of female breast cancer; ANOVA and SNK were performed to 
detect the significantly differences in treatment cost with different TNM stages. 
RESULTS: Direct medical expenditure was extracted from medical record and 
expense statement of 316 breast cancer cases in Sichuan Cancer Hospital; direct 
non-medical expenditure was investigated from 59 patients and their relatives; 
indirect expenditure was surveyed from 94 cases who received surgery more 
than one year ago. The average treatment cost of female breast cancer was 
RMB154,658 (US$24,854), which was adjusted by the proportions of ER, PR, and 
menses status of patients. The range of treatment cost from TNM 0 stage to TNM 
IV stage is RMB37,608-RMB207,824 (US$6,044-US$33,397). Breast cancer cases 
with early stage had considerably lower treatment cost than those with 
advanced stage. CONCLUSIONS: Early detection and treatment of breast cancer 
may have a real economic significance for reducing the burden of disease.  
 
PCN47  
THE IMPACT OF PROSTATE CANCER ON QUALITY OF LIFE  
Zyczynski TM1, Trudel GC2, Chen J3, Mallow PJ4, Penrod JR5, Rizzo JA6 
1Bristol-Myers Squibb, Princeton, NJ, USA, 2Bristol-Myers Squibb, Montréal, QC, Canada, 
3University of Maryland, College Park, MD, USA, 4S2 Statistical Solutions, Cincinnati, OH, USA, 
5Bristol-Myers Squibb, Plainsboro, NJ, USA, 6Stony Brook University, Port Jefferson, NY, USA  
OBJECTIVES: Studies have shown that men diagnosed with metastatic prostate 
cancer report significantly reduced quality of life (QoL) and have higher levels of 
depression and anxiety than men with localized prostate cancer. The present 
study assessed the impact of prostate cancer on health-related QoL compared to 
individuals without prostate cancer. METHODS: Using 1996-2009 data from the 
Medical Expenditure Panel Survey (MEPS), multivariate analyses were performed 
on three health status measures: 1) EuroQol EQ-5D, 2) Short Form (SF)-12 Health 
Survey, 3) Self-reported health status. All men age 40 and older with 
International Classification of Disease Codes, 9th revision of 185 were identified. 
RESULTS: The MEPS database included 1,399 patients with prostate cancer. Mean 
age was 72 years, and 71% were Caucasian. The EQ-5D results indicated that QoL 
was 5% lower for prostate cancer patients than individuals without prostate 
cancer (0.76 vs. 0.80, p < 0.001). Results of the SF-12 Physical Health Composite 
Scores (PCS) indicated that prostate cancer patients scored lower than 
individuals without prostate cancer (44.6 vs. 46.3 [population norm = 50],  
p < 0.001). Prostate cancer patients also rated themselves 12% lower on the self-
reported physical health status than individuals without prostate cancer (0.69 vs. 
0.78, p < 0.001). There was no significant difference in mental health of prostate 
cancer patients as measured by the SF-12 Mental Health Composite Score or self-
reported mental health status. CONCLUSIONS: These findings indicate that 
prostate cancer has a significant negative effect on physical health as measured 
by the EQ-5D, the SF-12 PCS, and patient self-report. Prostate cancer had no 
discernible effect on patients’ mental health. Further research on the effects of 
disease severity on QoL is warranted as literature indicates that there are few 
psychosocial interventions for patients with advanced disease.  
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OBJECTIVES: Patients diagnosed with metastatic (M1) prostate cancer (PCa) are 
predisposed to skeletal related events (SREs), including bone surgery (BS), 
pathologic fracture (PF) and spinal cord compression (SCC). There is limited 
information regarding the change in costs associated with SREs, by type, among 
stage IV M1 PCa patients. METHODS: We analyzed patients aged 66+ with an 
(AJCC) M1 PCa diagnosis. Cases diagnosed between 2000 and 2007 were identified 
from the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset. 
Patients were followed until death or censoring. Incremental costs per patient 
were calculated for the 12-month pre-period and the 12-month post-period 
relative to the first post-diagnosis SRE. Results were reported as the average 
percent change in the total pre-post period costs. Subgroup analysis was carried 
out separately for individuals who survived (survivors) and died (non-survivors) 
within the 12-month post-period. A sensitivity analysis was carried out for a  
6-month pre-post interval. The analysis was conducted from a US Medicare 
system perspective. RESULTS: Application of inclusion criteria resulted in 1,234 
stage IV M1, PCa patients with SREs. The average age was 78 years and 11% were 
African American. Five, mutually exclusive SRE groups were evaluated: PF-only 
(n=180), SCC-only (n=634), BS-only (n=200), PF with BS (n=163), SCC with BS 
(n=57). The average percent increase in the total costs in the post-period 
compared to the pre-period was 67%. The average percent increases in costs for 
each of the subgroups were as follows: PF-only, 53%; PF with BS, 71%; SCC-only, 
64%; SCC with BS, 88%; and BS-only, 70%. Subgroup analysis showed a 77% 
increase in total costs among survivors and a 60% increase in costs among non-
survivors. The average percent increase in SRE costs using a pre-post period of 6 
months was 75%. CONCLUSIONS: The percentage increase in costs post-SRE 
varies by type of SRE, survival post-SRE, and interval length.  
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OBJECTIVES: Costs for the population of metastatic castrate-resistant prostate 
cancer (mCRPC) patients can be difficult to discern due to the lack of a specific 
International Classification of Diseases, 9th Revision (ICD-9) code. This study 
described the resource utilization and costs of patients with mCRPC in a large US 
health claims database using chemotherapy administration as a proxy. 
METHODS: Data from January 1, 2006-June 30, 2011 from the MarketScan 
Commercial and Medicare databases were used in this analysis. Index date was 
defined as the first docetaxel, mitoxantrone, estramustine, vinorelbine, 
cabazitaxel or abiraterone treatment date between January 1, 2007 and June 30, 
2010. Additional inclusion criteria: >=18 years old; continuous pharmaceutical 
and medical enrollment >=6 months prior to and >=2 months following the index 
date; >=1 ICD-9 diagnosis code for prostate cancer (185.x). mCRPC related costs 
were identified by the presence of an ICD-9 code of 185.x on the claim. Costs 
were estimated separately for chemotherapy, radiation, inpatient, outpatient 
and emergency room (ER). Median per patient per month (PPPM) costs were 
calculated at the patient level. RESULTS: 4,005 patients were eligible, with a 
mean age of 70.2 years. For patients with medical utilization, total median PPPM 
costs increased from $3,107 pre-index to $6,939 post-index. Chemotherapy costs 
increased ($234 pre-index vs. $1,439 post-index), while radiation costs decreased 
($793 vs. $394). Excluding costs related to chemotherapy, radiation and other 
drug treatment, costs for inpatient, outpatient and ER visits increased from 
$2,120 pre-index to $4,388 post-index. Both mCRPC-related costs ($862 vs. $1,986) 
and non-mCRPC-related costs ($763 vs. $1,628) rose. CONCLUSIONS: These 
findings indicate that the cost burden from mCRPC is quite large. With aging of 
the population, prevalence of prostate cancer is expected to increase to 3.2 
million in the US by 2020 with costs continuing to escalate. Further research is 
needed to understand these cost implications, especially for the Medicare 
system.  
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OBJECTIVES: To assess the clinical burden, health care utilization, and cost 
patterns of prostate cancer patients in the U.S. veteran population. METHODS: A 
retrospective database analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with prostate cancer were identified 
using International Classification of Disease 9th Revision Clinical Modification 
(ICD-9-CM) diagnosis code 185.xx. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure clinical, cost, and 
utilization distribution in the sample. The most common comorbidities and 
treatment medications for prostate cancer patients were also examined. 
RESULTS: Among all study patients diagnosed with prostate cancer (n=251,890), 
the most common comorbidities were hypertension (n=69,534, 27.60%), elevated 
prostate-specific antigen (PSA) levels (n=45,498, 18.06%), and diabetes (n=34,171, 
13.57%). The most common treatment medications prescribed for prostate 
cancer patients were simvastatin (n=71,263, 28.29%), omeprazole (n=34,185, 
13.57%) and terazosin hydrochloride (n=22,639, 8.99%). A total of 117,599 (46.69%) 
patients had PSA test results, with an average result of 14.26. Percentages of 
inpatient (12.89%), emergency room (ER) (13.12%), physician office (99.86%), 
outpatient visits (99.87%), and pharmacy visits (90.34%) were calculated. Patient 
expenditures were found to be $4,227 (SD=$28,254) for inpatient, $146 (SD=$582) 
for ER, $6,469 (SD=$11,387) for physician office, $6,781 (SD=$11,837) for outpatient 
visits and $1,247 (SD=$4,159) for pharmacy visits. CONCLUSIONS: PSA laboratory 
test results should be considered when evaluating disease severity and 
progression of prostate cancer. However, the effects of prescribed medications 
on those test results should always be considered when interpreting laboratory 
results.  
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